Surgery and OncologySurgery and OncologyХирургия и онкология2949-5857Publishing House ABV Press53710.17650/2686-9594-2022-12-2-46-54LITERATURE REVIEWОБЗОР ЛИТЕРАТУРЫNeoadjuvant chemotherapy for colon cancerНеоадъювантная химиотерапия при раке ободочной кишкиFedyaninM. Yu.ФедянинМ. Ю.
Russian Federation

Mikhail Yuryevich Fedyanin

24 Kashirskoe Shosse, Moscow 115478

Михаил Юрьевич Федянин

115478 Москва, Каширское шоссе, 24

fedianinmu@mail.ruTryakinA. A.ТрякинА. А.
Russian Federation

24 Kashirskoe Shosse, Moscow 115478

115478 Москва, Каширское шоссе, 24

N. N. Blokhin National Medical Research Center of Oncology, Ministry of Health of RussiaФГБУ «Национальный медицинский исследовательский центр онкологии им. Н. Н. Блохина» Минздрава России0506202212246540506202205062022Copyright ©; 2022, ABV-pressCopyright ©; 2022, АБВ-пресс2022ABV-pressАБВ-прессhttps://onco-surgery.info/jour/about/editorialPolicieshttps://onco-surgery.info/jour/article/view/537

Promising results of neoadjuvant therapy have encouraged changes in treatment standards for many types of cancer, including triple negative and HER-positive breast cancer, gastric cancer, rectal cancer, etc. Preoperative chemotherapy can decrease the tumor burden, which might reduce the volume of surgery; it also improves the disease prognosis by reducing the number of viable tumor cells and micrometastases in regional lymph nodes; it increases the proportion of patients receiving systemic treatment, which often leads to an improved overall survival of patients; it enables the evaluation of tumor sensitivity to therapy, which also allows the investigation of tumor sensitivity to new pharmacological agents. However, colon cancer seems to stay away from these trends. This literature review focuses on studies analyzing neoadjuvant therapy for resectable colon cancer and analyzes the role of preoperative therapy in this disorder.

Обнадеживающие результаты неоадъювантной терапии определили изменение стандартов лечения большого числа нозологий в онкологии (тройной негативный и HER-положительный подтипы рака молочной железы, рак желудка, прямой кишки и т. д.). Проведение предоперационного лечения приводит к снижению стадии болезни, что должно уменьшать объем хирургического вмешательства; улучшает прогноз течения заболевания, уменьшая число жизнеспособных опухолевых клеток и микрометастазов в регионарных лимфатических узлах; увеличивает долю больных, которые получают системное лечение, что зачастую приводит и к улучшению общей выживаемости пациентов; позволяет оценивать чувствительность опухоли к проводимому лечению, что также открывает возможности изучения чувствительности опухоли к новым фармакологическим агентам. При этом рак ободочной кишки находится в стороне от общих тенденций. Целью данного обзора литературы являются изучение результатов исследований, посвященных неоадъювантному лечению при резектабельных стадиях рака ободочной кишки, и попытка найти место предоперационной терапии при данной патологии.

colon cancerneoadjuvant therapychemotherapyрак ободочной кишкинеоадъювантная терапияхимиотерапияRiva F., Bidard F.-C., Houy A. et al. Patient-specific circulating tumor DNA detection during neoadjuvant chemotherapy in triple-negative breast cancer. Clin Chem 2017;63(3):691–9. DOI: 10.1373/clinchem.2016.262337.Yang L., Wang Y., Shen L. et al. Predicting treatment outcome of rectal cancer patients underwent neoadjuvant chemoradiotherapy by ctDNA: the potential use of ctDNA monitoring as organ-sparing approach. J Clin Oncol 2018; 36(15 Suppl):3608. DOI: 10.1200/JCO.2018.36.15_suppl.3608.Body A., Prenen H., Latham S. et al. The role of neoadjuvant chemotherapy in locally advanced colon cancer. Cancer Manag Res 2021;13:2567–79.Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) investigators. Lancet 1995;345:939–44.Moertel C.G., Fleming T.R., Macdonald J.S. et al. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med 1990;322:352–8.O’Connell M.J., Mailliard J.A., Kahn M.J. et al. Controlled trial of fluorouracil and low-dose leucovorin given for 6 months as postoperative adjuvant therapy for colon cancer. J Clin Oncol 1997;15:246–50.Francini G., Petrioli R., Lorenzini L. et al. Folinic acid and 5-fluorouracil as adjuvant chemotherapy in colon cancer. Gastroenterology 1994;106:899–906.André T., Boni C., Navarro M. et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol 2009;27:3109–16.Yothers G., O’Connell M.J., Allegra C.J. et al. Oxaliplatin as adjuvant therapy for colon cancer: updated results of NSABP C-07 trial, including survival and subset analyses. J Clin Oncol 2011;29:3768–74.Schmoll H.J., Tabernero J., Maroun J. et al. Capecitabine plus oxaliplatin compared with fluorouracil/folinic acid as adjuvant therapy for stage III colon cancer: Final results of the NO16968 randomized controlled phase III trial. J Clin Oncol 2015;33:3733–40.Grothey A., Sobrero A.F., Shields A.F. et al. Duration of adjuvant chemotherapy for stage III colon cancer. N Engl J Med 2018;378:1177–88.McCleary N.J., Meyerhardt J.A., Green E. et al. Impact of age on the efficacy of newer adjuvant therapies in patients with stage II/III colon cancer: findings from the ACCENT database. J Clin Oncol 2013;31(20):2600–6. DOI: 10.1200/JCO.2013.49.6638.Smith N.J., Bees N., Barbachano Y. et al. Preoperative computed tomography staging of nonmetastatic colon cancer predicts outcome: implications for clinical trials. Br J Cancer 2007;96(7):1030–6. DOI: 10.1038/sj.bjc.6603646.Park S.Y., Cho S.H., Lee M. et al. Diagnostic performance of MRI versus MDCT-categorized T3cd/T4 for identifying high-risk stage II or stage III colon cancers: a pilot study. Abdom Radiol (NY) 2019;44(5):1675–85. DOI: 10.1007/s00261-018-1822-7.Nerad E., Lambregts D., Kersten E. et al. MRI for local staging of colon cancer: can MRI become the optimal staging modality for patients with colon cancer? Dis Colon Rectum 2017;60(4):385–92. DOI: 10.1097/DCR.0000000000000794.Hetta W., Niazi G., Abdelbary M. Accuracy of 18F-FDG PET/CT in monitoring therapeutic response and detection of loco-regional recurrence and metastatic deposits of colorectal cancer in comparison to CT. Egypt J Radiol Nuclear Med 2020;51:37.Brush J., Boyd K., Chappell F. et al. The value of FDG positron emission tomography/computerised tomography (PET/CT) in pre-operative staging of colorectal cancer: a systematic review and economic evaluation. Health Technol Assess 2011;15(35).Hunter C., Blake H., Jeyadevan N. et al. Local staging and assessment of colon cancer with 1.5-T magnetic resonance imaging. Brit J Radiol 2016:20160257.Rollven E., Holm T., Glimelius B. et al. Potentials of high resolution magnetic resonance imaging versus computed tomography for preoperative local staging of colon cancer. Acta Radiol 2013;54:722–30.Dighe S., Swift I., Magill L. et al. Accuracy of radiological staging in identifying high-risk colon cancer patients suitable for neoadjuvant chemotherapy: a multicentre experience. Colorectal Dis 2012;14:438–44.Nerad E., Lahaye M.J., Maas M. et al. Diagnostic accuracy of CT for local staging of colon cancer: a systematic review and meta-analysis. AJR Am J Roentgenol 2016:1–12.Tsunoda Y., Ito M., Fujii H. et al. Preoperative diagnosis of lymph node metastases of colorectal cancer by 18FDG-PET-CT. Jpn J Clin Oncol 2008;38:347–53.Tateishi U., Maeda T., Morimoto T. et al. Non-enhanced CT versus contrast enhanced CT in integrated 18FDG PET-CT studies for nodal staging of rectal cancer. Eur J Nucl Med Mol Imaging 2007;34:1627–34.Dehal A., Graff-Baker A., Vuong B. et al. Correlation between clinical and pathologic staging in colon cancer: implications for neoadjuvant treatment. J Gastrointest Surg 2018;22(10):1764–71. DOI: 10.1007/s11605-018-3777-y.Dehal A., Graff-Baker A., Vuong B. et al. Neoadjuvant chemotherapy improves survival in patients with clinical T4b colon cancer. J Gastrointest Surg 2018;22(2): 242–9. DOI: 10.1007/s11605-017-3566-z.De Gooyer J.-M., Verstegen M., Lam-Boer J. et al. Neoadjuvant chemotherapy for locally advanced T4 colon cancer: a nationwide propensity-score matched cohort analysis. Dig Surg 2020;37(4): 292–301. DOI: 10.1159/000503446.Arredondo J., Baixauli J., Pastor C. et al. Mid-term oncologic outcome of a novel approach for locally advanced colon cancer with neoadjuvant chemotherapy and surgery. Clin Transl Oncol 2017;19(3):379–85. DOI: 10.1007/s12094-016-1539-4.De Gooyer J.M., Verstegen M.G., Lam-Boer J. et al. Neoadjuvant chemotherapy for locally advanced T4 colon cancer: a nationwide propensityscore matched cohort analysis. Dig Surg 2020;37(4):292–301. DOI: 10.1159/000503446.Jakobsen A., Andersen F., Fischer A. et al. Neoadjuvant chemotherapy in locally advanced colon cancer. A phase II trial. Acta Oncol 2015;54(10):1747–53. DOI: 10.3109/0284186X.2015.1037007.Zhou H., Song Y., Jiang J. et al. A pilot phase II study of neoadjuvant triplet chemotherapy regimen in patients with locally advanced resectable colon cancer. Chin J Cancer Res 2016;28(6):598–605. DOI: 10.21147/j.issn.1000-9604.2016.06.06.Liu F., Yang L., Wu Y. et al. CapOX as neoadjuvant chemotherapy for locally advanced operable colon cancer patients: a prospective single-arm phase II trial. Chin J Cancer Res 2016;28(6):589–97. DOI: 10.21147/j.issn.1000-9604.2016.06.05.Karoui M., Gallois C., Piessen G. et al. Does neoadjuvant FOLFOX chemotherapy improve the prognosis of high-risk Stage II and III colon cancers? Three years’ follow-up results of the PRODIGE 22 phase II randomized multicentre trial. Colorectal Dis 2021;23(6):1357–69. DOI: 10.1111/codi.15585.Glasbey J., Seligmann J., Morton D.G., FOxTROT Collaborating Group. Risk of bowel obstruction in patients undergoing neoadjuvant chemotherapy for high-risk colon cancer: A nested casecontrol matched analysis of an international, multi-centre, randomised controlled trial (FOxTROT). Ann Oncol 2021;32(Suppl 5):S530–S582. DOI: 10.1016/annonc/annonc698.Collaborative Group F, FOxTROT Collaborative Group. Feasibility of preoperative chemotherapy for locally advanced, operable colon cancer: the pilot phase of a randomised controlled trial. Lancet Oncol 2012;13(11):1152–60. DOI: 10.1016/S1470-2045(12)70348-0.Seymour M.T., Morton D., International FOxTROT Trial Investigators. FOxTROT: an international randomised controlled trial in 1052 patients (pts) evaluating neoadjuvant chemotherapy (NAC) for colon cancer. J Clin Oncol 2019;37(15 Suppl):3504. DOI: 10.1200/JCO.2019.37.15_suppl.3504.Pietrantonio F., Miceli R., Raimondi A. et al. Individual patient data meta-analysis of the value of microsatellite instability as a biomarker in gastric cancer. J Clin Oncol 2019;37(35):3392–400. DOI: 10.1200/JCO.19.01124.Fedyanin M.Yu., Elsnukaeva Kh.Kh., Tryakin A.A., Tjulandin S.A. Some aspects of immunotherapy for colon cancer. Tazovaya khirurgiya i onkologiya = Pelvic Surgery and Oncology 2018;8(1):19–27. (In Russ.). DOI: 10.17650/2220-3478-2018-8-1-19-27.Федянин М.Ю., Эльснукаева Х.Х., Трякин А.А., Тюляндин С.А. Некоторые аспекты иммунотерапии при раке толстой кишки. Тазовая хирургия и онкология 2018;8(1):19–27. DOI: 10.17650/2220-3478-2018-8-1-19-27.Chalabi M., Fanchi L.F., Dijkstra K.K. et al. Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers. Nat Med 2020;26 (4):566–76. DOI: 10.1038/s41591-020-0805-8.Ludford R., Raghav K., Blum Murphy M.A. et al. Neoadjuvant pembrolizumab in localized/locally advanced solid tumors with mismatch repair deficiency. Ann Oncol 2021;32(Suppl 5):S1211–S1226. DOI: 10.1016/annonc/annonc716.Li D., Wang Y., Liu W. et al. The correlation between 18F-FDG PET/CT imaging SUVmax of preoperative colon cancer primary lesions and clinicopathological factors. J Oncol 2021;2021:4312296. DOI: 10.1155/2021/4312296.Hendlisz A., Deleporte A., Van Laethem J.-L. et al. Preoperative (preop) chemosensitivity testing as predictor of treatment benefit in adjuvant stage III colon cancer (CC): Interim analysis of the PEPITA study. J Clin Oncol 2014;32(Suppl 3):abstr. 385.Hendlisz A., Caparica R., Deleporte A. et al. Preoperative chemosensitivity testing as predictor of treatment benefit in adjuvant stage III colon cancer: Preliminary analysis of the PePiTA study. J Clin Oncol 2019;37(15 Suppl):3610.